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ABSTRACT: We report a double-click macrocyclization approach
for the design of constrained peptide inhibitors having non-helical or
extended conformations. Our targets are the tankyrase proteins
(TNKS), poly(ADP-ribose) polymerases (PARP) that regulate Wnt
signaling by targeting Axin for degradation. TNKS are deregulated in
many diﬀerent cancer types, and inhibition of TNKS therefore
represents an attractive therapeutic strategy. However, clinical
development of TNKS-speciﬁc PARP catalytic inhibitors is
challenging due to oﬀ-target eﬀects and cellular toxicity. We instead
targeted the substrate-recognition domain of TNKS, as it is unique
among PARP family members. We employed a two-component
strategy, allowing peptide and linker to be separately engineered and
then assembled in a combinatorial fashion via click chemistry. Using the consensus substrate-peptide sequence as a starting point,
we optimized the length and rigidity of the linker and its position along the peptide. Optimization was further guided by high-
resolution crystal structures of two of the macrocyclized peptides in complex with TNKS. This approach led to macrocyclized
peptides with submicromolar aﬃnities for TNKS and high proteolytic stability that are able to disrupt the interaction between
TNKS and Axin substrate and to inhibit Wnt signaling in a dose-dependent manner. The peptides therefore represent a
promising starting point for a new class of substrate-competitive inhibitors of TNKS with potential for suppressing Wnt signaling
in cancer. Moreover, by demonstrating the application of the double-click macrocyclization approach to non-helical, extended, or
irregularly structured peptides, we greatly extend its potential and scope, especially given the frequency with which such motifs
mediate protein−protein interactions.
■ INTRODUCTION
The development of eﬀective strategies for modulating
protein−protein interactions (PPIs) has the potential to vastly
expand the range of druggable proteins. Targeting the typically
large, ﬂat surfaces involved with molecules of high aﬃnity and
speciﬁcity can be readily achieved by mimicking the natural
binding partner protein’s interacting surface in the form of
constrained peptides or peptidomimetics (reviewed in refs
1−5). The constraint serves the dual purpose of preorganizing
the structure and thereby increasing the binding aﬃnity as well
as enhancing the pharmacokinetic properties such as in vivo
stability and cell penetration.6−9 Toward this goal, a class of
molecules called “stapled” or constrained peptides have been
developed, which are characterized by a bioactive, α-helical
conformation that is induced by chemically cross-linking two
side chains.10−18 Constraining non-helical, extended, or
irregularly structured peptide motifs presents a diﬀerent
challenge, as it is harder to rationally design a linker so as to
stabilize a binding-competent conformation (e.g., ref 19). Given
that these types of motifs are found in up to 50% of all PPIs,20
there is a pressing need to address this challenge.
Here, we use a two-component double-click chemistry
approach to macrocyclize peptides in an extended, non-helical
conformation. Our targets are the tankyrase proteins. Tank-
yrase 1 and tankyrase 2 (subsequently referred to as TNKS) are
poly(ADP-ribose) polymerases (PARPs) involved in a number
of cellular processes. These include control of the mitotic
checkpoint,21−23 regulation of telomere length by targeting
telomeric repeat binding factor 1 (TRF1) for degradation,24−28
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and regulation of Wnt signaling by targeting Axin for
degradation.29,30 Altered TNKS expression or activity is
implicated in various disease states, and increased expression
of TNKS has been observed in many diﬀerent cancers including
breast cancers, ﬁbrosarcoma, ovarian cancer, glioblastoma,
pancreatic adenocarcinoma, and gastric cancer.28,31−34 As
cancer therapeutics, TNKS inhibitors could potentially exploit
tumor-speciﬁc Wnt dependency (e.g., in colorectal cancers with
APC and KRAS mutations, which are resistant to epidermal
growth factor receptor inhibitors) or target telomere
dysfunction or an enhanced mitotic rate. It has also been
shown that silencing of TNKS by RNAi has a synthetic lethality
eﬀect in tumor cells with BRCA1/BRCA2 gene defects but has
minimal eﬀects in wild-type cells.32 Thus, TNKS inhibitors, like
PARP inhibitors, may be useful for the treatment of breast
cancers caused by mutations in the BRCA genes.35−37
Furthermore, TNKS inhibitors may additionally have broader
clinical applications. For example, the Wnt pathway has been
found to be a valid target for treating neurodegenerative
diseases (reviewed in refs 38 and 39), such as multiple
sclerosis40,41 and amyotrophic lateral sclerosis.42,43 More
recently, TNKS have been found to play a role in glucose
homeostasis44 in type II diabetes.
The ﬁrst small-molecule TNKS inhibitor29 (discovered in a
Wnt pathway inhibitor screen) and those developed sub-
sequently45−48 are all directed against the catalytic PARP
domain; however, there are problems of cellular toxicity due to
oﬀ-target eﬀects arising from the NAD+/ADP ribose-like
characteristic of these active-site inhibitors (reviewed in refs 35
and 49−51). The TNKS proteins have a domain structure that
is distinct from other PARP family members, as they contain an
ankyrin domain comprising a series of ankyrin-repeat clusters
(ARCs) that are involved in targeting speciﬁc proteins for
PARylation (Figure 1a). Our aim herein was therefore to
develop a new class of highly speciﬁc TNKS inhibitors by
targeting the substrate-recognition domain. Moreover, Guettler
et al. have recently shown that TNKS can induce Wnt signaling
independently of its catalytic PARP activity, mediated instead
via an ARC-domain scaﬀolding function and thus suggesting
additional advantages of therapeutic targeting of this domain.52
To this end, we have designed a series of macrocyclized
peptides using a modular two-component strategy that employs
click chemistry to connect a linker and a peptide, thus allowing
each to be varied independently before assembling them in a
combinatorial fashion.55,56 Our designs were guided by the
previously determined crystal structures of substrate-derived
peptides in complex with the fourth ARC domain of TNKS2
(TNKS2 ARC4) (Figure 1b)53 and subsequently optimized
with the help of molecular dynamics (MD) simulations using
an iterative process of modifying the length and rigidity of the
linker as well as its position along the peptide sequence. We
determined the crystal structures of two of the macrocyclized
peptides in complex with TNKS, leading to further
optimization of the design. We show that these peptides are
able to disrupt tankyrase-substrate complexes in vitro and to
inhibit Wnt transcription in a dose-dependent manner. Thus,
our results provide a promising starting point for a new class of
substrate-competitive inhibitors of tankyrase. Moreover, the
methodology has the potential to be a general approach for
inhibiting PPIs that involve non-helical, extended, or irregularly
structured molecular recognition motifs.
■ RESULTS
Peptide and Linker Design. We focused the design and
optimization strategy on an 8-residue consensus sequence,
REAGDGEE, derived previously from a mutational analysis of
TNKS substrates.53 In that study, a 10-residue peptide was
found to be suﬃcient for high-aﬃnity TNKS binding; we
demonstrate here that further truncation to the 8-core binding
residues does not weaken the aﬃnity of the peptide.
Computational alanine scanning was ﬁrst carried out on
structures extracted from three independent 50 ns MD
simulations of the complex between TNKS2 ARC4 and the
8-residue consensus sequence (for which there are no available
Figure 1. Structure of TNKS1 and TNKS2. (a) Domain architecture, comprising a homopolymeric run of histidine, proline and serine (HPS)
residues, the ankyrin repeat cluster (ARC), sterile alpha motifs (SAM), and catalytic PARP domains. (b) Structure of human TNKS2 ARC4 (gray
cartoon) in complex with substrate peptide LPHLQRSPPDGQSFRS (purple; PDB ID: 3TWR);53 for clarity, only the central part of the peptide (in
bold) is labeled. (c) Structure of mouse TNKS1 ARC2−3 (gray cartoon) in complex with mouse Axin1_1−80; only residues 18−30 (green) and
60−78 (yellow) of mAxin1 are visible in the crystal structure (PDB ID: 3UTM).54
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experimental structures) to assess which positions would be
amenable to replacement by an unnatural amino acid (UAA)
having azido functionality for conjugation to the linker. The
analysis indicated Arg1 to be an important hot-spot residue,
whereas Ala3 (mutated to Gly in the computational analysis),
Asp5, and Glu8 make only modest contributions to the
interaction (Figure S1). The modeling also suggests that
positions 4 and 6 are unfavorable for cross-linking due to a high
likelihood of steric clashes of their side chains with the protein
surface. Mutations of Glu2 and Glu7 were found to be
stabilizing, indicating that the wild-type residues are detrimental
to binding and consequently amenable to replacement by
UAAs. Thus, a ﬁrst panel of macrocyclized peptides was
synthesized with azido-functionalized UAAs at positions 2 or 3
and 7 or 8 (Figure 2a), and they were acetylated at the N-
terminus to neutralize the terminal charge. The UAA side
chains are denoted n1−n4 to indicate the number of methylene
(CH2) units (Figure 2a).
We explored a number of diﬀerent linker designs, varying
both the chemical properties and rigidity (Figure 2b). All
linkers contained an alkyne at each terminus to cross-link the
two UAAs in the peptide. Linkers with linear aliphatic units
between the two alkynyl groups are denoted m3−m5 to
indicate the number of methylene (CH2) units. These linkers
were commercially available. A longer linker containing
hydrocarbon units and a urea derivative, which we denote as
m7N, was synthesized from 1,1′-carbonyldiimidazole and 1-
amino-3-butyne (protocols modiﬁed from ref 57). The linkers
with greater rigidity, m3c and m5c, contain aromatic groups
and were synthesized using palladium-catalyzed coupling
chemistry.56,58
The Double-Click Reaction Can Eﬀectively Macro-
cyclize Extended Peptides. We previously used our double-
click chemistry strategy to staple α-helical peptides derived
from the tumor suppressor p53 for inhibition of the p53-Mdm2
interaction.56 In that case, as for other helix stapling methods,
the stapling positions were identiﬁed to be the i, i+4 or i, i+7
residue pairs so that the intrinsic helical propensity of the
peptide brings the two stapling positions close together in
space, thereby helping to drive the reaction.6−8 The TNKS-
bound peptides adopt an extended conformation, and there-
fore, we ﬁrst tested the eﬃciency of the click reaction between
linker and peptide in this context. After optimization of the
reaction conditions, we were able to show that the click
reaction between peptide cp4n4 and linker m5 proceeded to
completion after stirring overnight under nitrogen in degassed
solvent (Figure 2c). Monitoring by liquid chromatography mass
spectrometry (LCMS) showed that no starting material
remained and that there was a single product with the expected
mass. The puriﬁed and lyophilized product was further analyzed
by infrared spectrometry (IR) and high-resolution mass
spectrometry to verify that the two azido groups in the peptide
reacted with the same linker because other potential byproducts
share the same mass from the 1,3-dipolar cycloaddition. The
disappearance of the typical azido stretch at 2100 cm−1 in the
IR spectrum after the reaction suggested that both azido groups
had reacted (Figure S4). The isotopic patterns from mass
spectrometry showed a mass spacing between two [M + 2H]2+
species of 0.5 amu, consistent with the cross-linking of a single
linker onto one peptide (Figure S5). These results demonstrate
unequivocally that we can extend the scope of our two-
component click macrocyclization strategy to non-helical
peptides.
The aﬃnities of a ﬁrst panel of macrocyclized peptides for
binding to TNKS2 ARC4 were determined using a competitive
ﬂuorescence polarization (FP) assay with a TAMRA-labeled
linear peptide T-pep1 (TAMRA-Ahx-REAGDGEE, where Ahx
is a spacer that comprises 6-aminohexanoic acid; TAMRA-
Figure 2. Macrocyclic peptide design. (a, left) Sequences of the synthesized peptides with the UAAs denoted as ‘X’; (right) chemical structures of
the diﬀerent UAA side chains, where n2, n3, and so forth indicate the number of CH2 units in the side chain. (b) Chemical structures of the linkers,
where m3−m5 indicate the number of carbon/nitrogen atoms between the two alkynyl groups. (c) Schematic of the click reaction between the
peptides in (a) and linkers in (b); see Figure S2 for full chemical structures of representative peptides.
Journal of the American Chemical Society Article
DOI: 10.1021/jacs.6b10234
J. Am. Chem. Soc. 2017, 139, 2245−2256
2247
labeled peptides are indicated with “T-” at the beginning of the
name) as the competing ligand (Figure 3 and Table S1). The
dissociation constant of the labeled T-pep1 was 0.8 ± 0.1 μM
from the direct FP measurement, and that of unlabeled pep1
was 1.2 ± 0.1 μM from the competitive FP measurement in
agreement with the values reported in the literature.53 Two
uncross-linked precursor peptides, cp4n4 and cp5n4, were also
tested and found to have aﬃnities that were similar to or only
slightly weaker than pep1, indicating that incorporation of the
UAAs did not signiﬁcantly perturb the interaction with TNKS
ARC4. All of the macrocyclized peptides in this ﬁrst panel
bound more weakly than the linear pep1 to TNKS ARC4. We
tested several combinations of UAAs and linkers based on
cross-linking positions 2 and 7 (RXAGDGXE; cp2), including
varying the UAA side chain lengths (n) between 2 and 4, and
two diﬀerent linker lengths (m) of 5 and 7; however, all
combinations yielded peptides that exhibited very weak binding
aﬃnities. Macrocyclization of cp3, containing UAAs in
positions 2 and 8, also yielded weak binding aﬃnities.
Macrocyclization of cp4 and cp5 (UAAs in positions 3 and
7/8), however, yielded higher binding aﬃnities, and peptide
REXGDGXE (cp4) was therefore chosen for further
optimization.
Crystal Structures of TNKS2 in Complex with the
Macrocyclized Peptides. To aid the design process, we
determined the structure of cp4n4m5 (Figure S2) in complex
with TNKS2 ARC4 (Figure 4 and Figures S6 and S7). This
structure shows that the binding mode of the macrocyclized
peptide is very similar to that of the natural peptides.
Speciﬁcally, Arg1 of cp4n4m5 forms two salt bridges with
Glu598 and Asp589 of TNKS2 ARC4 (Figure S6a) and Glu2
with TNKS2 Lys557 (Figure S6b). The side chains of the two
UAAs, UAA3 and UAA7, point away from the protein surface,
which is crucial for their ability to form a macrocycle that does
not interfere with protein binding (Figure 4b). Between UAA3
and UAA7, residues Gly4, Asp5, and Gly6 of the peptide ﬁt
inside a groove on the protein surface (Figure 4a and Figure
S6c) with hydrogen bonding between Asp5 and TNKS2 Ser527
(Figure S6d) and the phenol rings of Tyr569 and Tyr536
stacking in parallel on either side of Gly6 (Figure S6c). The C-
terminal residue of cp4n4m5, Glu8, interacts with TNKS2
Lys604 via a salt bridge (Figure S6e). We note that the linker is
positioned away from the binding surface and does not perturb
the interactions between cp4n4m5 and TNKS2 ARC4 (Figure
4b), and it should therefore be possible to install additional
functionalities on the linker without compromising the binding
interface. Despite the high 1.35 Å resolution of the crystal
structure, parts of the UAA side chains and the triazole-
containing linkage are poorly deﬁned in the election density
(Figure 4b). This suggests that shortening the UAA side chains
and the linker should lead to tighter binding by further
reducing conformational ﬂexibility.
Figure 3. Determining the optimal peptide-linker combination.
Dissociation constants were determined by competitive FP assay
using labeled T-pep1 bound to ARC4 as the tracer for the ﬁrst panel of
macrocyclized peptides in which we varied the positions of the two
UAAs (denoted X) in the peptide sequence, the lengths of the side
chains, and the length of the linker. “n” is the number of methylene
(CH2) groups in the side chain of the UAAs; ‘m’ is the number of
carbon/nitrogen atoms between the two triazole groups in the linker.
Special linkers are m5c, a rigid linker based on napthalene, and m7N, a
linear linker made from a urea derivative described earlier. A dash in
the “m” box denotes uncross-linked peptide. The dissociation constant
of the unlabeled linear peptide, pep1, is shown for comparison.
Uncross-linked cp4n4 and cp5n4 were measured as comparisons to
their cross-linked counterpart. A full list of dissociation constants is
given in Table S1.
Figure 4. (a) Crystal structure of TNKS2 ARC4 (gray surface) in complex with the macrocyclized peptide cp4n4m5 (orange carbons; linker in red).
(b) 2Fobs − Fcalc electron density (blue mesh) of the linker and of the central residues of the peptide (orange; linker in red) contoured at 1σ, rotated
approximately 90° along the horizontal axis compared to (a).
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Consequently, we next synthesized UAAs with shorter side
chains and incorporated them into the cp4 sequence. All of the
peptides were synthesized with a TAMRA label at the N-
terminus (TAMRA-Ahx-REXGDGXE) for use in the direct FP
assay format. The number (n) of CH2 groups in the side chain
of each UAA was varied between 1 and 3, and the number of
carbon/nitrogen atoms (m) between the two triazole groups in
the linker was varied between 3 and 5 (Figure 5a and b and
Table S2). We found that the binding aﬃnity was always
weakened when non-identical UAAs were used in the same
peptide, and it was greatly weakened with UAA side chain
length of n = 1. Upon shortening of the linker, the binding
aﬃnity progressively increased, and rigidifying the linker by
incorporating an aromatic moiety (linker m3c) resulted in a
further increase of the aﬃnity. The macrocyclized peptide with
the highest binding aﬃnity had n = 2 for both UAA side chains
and the rigid linker m3c (labeled T-cp4n2m3c, Figures S2 and
S3); its aﬃnity is approximately 2-fold higher than that of the
linear peptide T-pep1.
We then synthesized the unlabeled version of the highest
aﬃnity peptides from this second round of design and
determined the structure of TNKS2 ARC4 in complex with
one of them, cp4n2m3 (Figure 5, and Figures S2, S3, and S7a).
When comparing this structure with that of TNKS2 ARC4-
cp4n4m5 and those of previously published natural peptides,53
we can see that the linkers of both cp4n4m5 and cp4n2m3 are
long enough to retain the binding mode of the natural peptide
(Figure S7b). Additionally, the TNKS2 protein itself appears to
Figure 5. (a) Direct FP measurements for a subset of the second panel of TAMRA-labeled peptides based on the cp4 sequence (TAMRA-Ahx-
REXDGDXE) with (b) their binding aﬃnities listed in a table (see Table S2 for the full list of peptides and their binding aﬃnities). The Kd for T-
cp4n1m3 is not detectable (n.d.). (c) Crystal structure of TNKS2 ARC4 (gray surface) in complex with macrocyclized peptide cp4n2m3 (cyan;
linker in green). Superposition of cp4n2m3 (cyan/green) and cp4n4m5 (orange/red) in the two structures of the complexed peptides; TNKS2
ARC4 is shown in gray. (d) 2Fobs − Fcalc electron density, contoured at 1σ, of the linker and of the central residues of peptide cp4n2m3. (e) Overlay
of the three structures: the complex with the natural substrate peptide LPHLQRSPPDGQSFRS is shown (PDB ID: 3TWR)53 (protein: pink;
peptide: purple). Ankyrin repeats 4 and 5 of TNKS2 ARC4-cp4n2m3 (cyan) move by 2−3 Å compared to those in the complex with cp4n4m5
(orange) and the linear peptide (pink). (f) CD spectra of linear peptides pep1 (green) and cp4n4 (red) and of cross-linked peptides cp4n4m5
(orange), cp4n2m3 (cyan), and the non-binding cross-linked peptide cp4n1m3 (purple).
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have some ﬂexibility for accommodating the slightly diﬀerent
conformations of the peptides.
Both peptides are more ﬂexible at their respective termini
(see Figures S7 and S8), whereas the central regions make close
contacts with TNKS2 ARC4 and adopt virtually identical
conformations in the two macrocyclized peptides (Figure 5c).
The central residues Gly4-Asp5-Gly6 are deeply inserted into a
binding cleft of the protein, forming several hydrogen bonding
interactions as well as remarkable π-stacking interaction,
wherein Gly6 is sandwiched between Tyr536 and Tyr569
(Figures 4b and 5d and Figure S7c). Shortening of the UAA
side chains and the hydrocarbon linker rigidiﬁes the macro-
cycle, which is corroborated by the better-deﬁned electron
density of cp4n2m3 (Figure 5d and Figure S7d). The shorter
linker of cp4n2m3 pulls the side chains of peptide residues 3
and 7 slightly inward when compared with that of the wild-type
peptide (PDB ID: 3TWR)53 and cp4n4m5 (Figure 5c and
Figure S7b).
This diﬀerence appears to have an eﬀect on the overall
protein curvature, whereby ankyrin repeats 4 and 5 move by 2−
3 Å (Figure 5e). Although we cannot exclude a crystallization
artifact caused by changes in the packing of the complexes in
the two diﬀerent crystal forms (Table S3), we could not
observe a change of this type in any of the previously published
linear peptide complexes (PDB IDs: 3TWR, 3TWS, 3TWT,
3TWU, 3TWV, 3TWW, and 3TWX),53 and the resolution of
1.33 Å should be suﬃcient to reliably observe these diﬀerences.
This alternative conformation was very similar to the crystal
structure of the apo protein (PDB ID: 3TWQ; Figure S9a)
with the only discernible diﬀerence found in ankyrin repeat 5.
Accordingly, this change in protein conformation mainly aﬀects
the C-terminal end of the bound peptide: whereas Glu8 of
cp4n4m5 forms a salt bridge with Lys604 (Figure S6e), in
cp4n2m3, it instead forms an interaction with Lys602 (Figure
S6f). Observed intermittently in MD simulations of the TNKS2
ARC4-pep1 complex (Figure S9b), this “apo-like” bound
conformation allows for the formation of a novel water
network that connects Glu8 and Lys602 with the triazole
moiety of UAA3 in the TNKS2 ARC4-cp4n2m3 complex. An
MD simulation of the isolated TNKS2 ARC4 sampled mainly
the apo-like bound conformation (Figure S9c). Conformations
that are somewhat similar to those observed in the linear
peptide and cp4n4m5 complexes, except for slight diﬀerences
in ankyrin repeats 3 and 5, were also sampled (Figure S9c). The
fact that the unbound protein is able to adopt the apo-like
bound conformation prior to binding suggests that conforma-
tional selection plays a dominant role in the binding of
cp4n2m3, whereas the requirement for modest conformational
changes in two of the ankyrin repeats suggests that induced ﬁt
mechanism is likely to be prominent in the binding of the linear
peptides and cp4n4m5.
To better understand the eﬀect of the diﬀerent macrocycles
on the conformations of the peptides and how any diﬀerences
might translate into the order of binding abilities observed, we
performed circular dichroism (CD) on the unlabeled peptides
(Figure 5f). We ﬁnd that linear pep1 and uncross-linked cp4n4
exhibit a random-coil conformation, as does the macrocyclic
cp4n4m5. For the higher-aﬃnity binder cp4n2m3, although its
CD spectrum resembles that of a random coil with a minimum
at 196 nm, it also has a small positive maximum at 217−218 nm
similar to that of a collagen;59 this distinctive secondary
structure is presumably due to the tighter constraint restricting
the ﬂexibility of the peptide backbone. It is consistent with our
goal of designing the macrocycles to restrict the conformations
of the peptides to reduce the entropy cost of binding as further
evidenced in the isothermal titration calorimetry data shown
below. When we further reduce the length of the macrocycle in
cp4n1m3, a macrocyclic peptide with nondetectable Kd for
TNKS2 ARC4 (Figure 5a and b and Table S2), the CD
spectrum indicates that an α-helical structure is induced by the
tighter constraint. Analysis of the crystal structures also shows
clearly that shorter UAAs (n = 1) would constrain the
macrocycle too much for the peptide to form ideal interactions
with the protein, leading to the observed weaker binding for n =
1 peptides (Table S2).
Macrocyclized Peptides Are Resistant to Proteolytic
Degradation. For the eﬀects of macrocyclization on peptide
stability to be tested, representatives of both the linear and the
macrocyclized peptides were subjected to proteolytic degrada-
tion using the AspN protease, which cleaves the N-terminal to
aspartates, in this case, Asp5, which is located within the
macrocycle. Protection of the central residues, Gly4-Asp5-Gly6,
is crucial for the integrity of the peptide for ﬁtting inside the
binding groove of the protein. TAMRA-labeled peptides were
used for monitoring the degradation based on the TAMRA
signal at 550 nm wavelength. The majority of the linear peptide,
T-pep1, was degraded within 1 h at room temperature, whereas
nearly 100% of the macrocyclized peptide, T-cp4n2m3,
remained intact after 4.5 h of peptidase treatment (Figure
S10a). No mass corresponding to the possible degraded
products could be found in the sample of the treated T-
cp4n2m3 after 4.5 h (Figure S10b). These results show that
macrocyclization greatly enhances the stability of the peptide.
Thermodynamics of the TNKS−Peptide Interactions.
Isothermal titration calorimetry (ITC) was used to characterize
the thermodynamics of the TNKS−peptide interactions
(Figure 6, Figure S11, and Tables S4 and S5). The smaller
−TΔS terms obtained for the macrocyclized peptides
compared with linear peptide pep1 are consistent with the
goal of macrocyclization, which is to lock the peptide in an
active conformation and thereby minimize the entropic cost of
binding (Figure 6). Furthermore, a smaller −TΔS value was
Figure 6. Thermodynamic parameters obtained for the binding of the
peptides to TNKS2 ARC4 and to TNKS1 ARC2−3, as measured by
ITC. Error bars are those obtained from standard derivation of the
mean from duplicate measurements.
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obtained for peptide cp4n2m3c with the more rigid linker
compared with that of cp4n2m3, consistent with the success of
this design feature.
TNKS proteins contain ﬁve ARCs, of which ARC2, 4, and 5
have sites for recognition by TNKS binding motifs. We
therefore also tested the binding of the peptides to TNKS1
ARC2−3, a construct containing ARC2 and (non-binding)
ARC3, whose structure had previously been solved.54 We
obtained similar results to TNKS2 ARC4 in terms of the
relative ΔS values of pep1 and the two macrocyclized peptides.
We note that all of the peptides tested bound more tightly to
TNKS1 ARC2−3 than to TNKS2 ARC4 (Tables S4 and S5),
although the two ARC domains share almost identical residues
at the binding interfaces.
We next compared the thermodynamic parameters of the
peptides with those of the TNKS substrate Axin. Axin is a rate-
limiting component of the β-catenin destruction complex in the
Wnt sigaling pathway, and PARylation of Axin by TNKS leads
to Axin degradation by the proteasome. The crystal structure of
mouse TNKS1 ARC2−3 had previously suggested that
dimerization of ARC2−3 occurs upon interaction with a
fragment (residues 1−80) of mouse Axin154 because this
fragment contains not one but two TNKS binding motifs, both
of which are similar in sequence to the consensus sequence
deduced by Guettler et al.53 (Figure 1c). The two motifs of
Axin (residues 18−30 and 60−79) each interact with one
ARC2 subunit in the ARC2−3 dimer. We performed ITC using
fragments of human Axin1, which share high homology to the
mouse counterparts. Our ITC data are consistent with the
dimerization of TNKS1 ARC2−3 seen in the crystal structure
in that we also observe a stoichiometry of two TNKS1 ARC2−
3 molecules binding to one Axin1_1−80 molecule (Table S5);
a stoichiometry of 1 was obtained for the interaction of TNKS2
ARC4 with Axin1_1−80. Furthermore, the TNKS2 ARC4
binding aﬃnity of Axin1_1−43 (containing only the N-
terminal TNKS-binding motif) was similar to that of
Axin1_1−80 (containing both motifs) (Table S4), indicating
that the N-terminal motif is the main contributor to the
TNKS2 ARC4 interaction, as was found to be the case for the
TNKS1 ARC2−3 interaction.54 Lastly, the ITC data show that
both cp4n2m3 and cp4n2m3c are better binders than Axin1 to
TNKS1 ARC2−3 as well as to TNKS2 ARC4, a result that was
also conﬁrmed by ﬂuorescence polarization (Tables S4 and S5).
The Macrocyclized Peptides Disrupt the TNKS−Axin
Interaction. Next, we tested the ability of the peptides to
disrupt the TNKS−Axin interaction using an in vitro pull-down
assay with TNKS2 ARC4 and GST-tagged human Axin1_1−80
immobilized on glutathione beads (Figure 7). The immobilized
TNKS2 ARC4-Axin1_1−80 complex was incubated with
increasing concentrations of linear peptide pep1 or macro-
cyclized peptide cp4n2m3 for 0.5 h. After washing the resin, the
proteins remaining bound to the resin were analyzed by SDS-
PAGE. The results show that pull-down of TNKS2 ARC4 was
disrupted by the peptides in a dose-dependent manner.
Macrocyclized peptide cp4n2m3 was a slightly better inhibitor
than pep1 (IC50 of ∼20 and ∼40 μM, respectively), reﬂecting
its slightly higher TNKS binding aﬃnity.
Incorporation of Cell-Penetrating Capability into the
Peptide Linker. We attached one of four diﬀerent cell-
penetrating peptide (CPP) sequences onto cp4n2m3c via the
linker by synthesizing the CPP sequences with the m3c linker
conjugated to their N-termini (see schematic in Table S6). The
two-component double-click reaction was then performed
between the CPP-conjugated m3c linker and the peptide T-
cp4n2 (TAMRA-Ahx-REXGDGXE, where X is n2). In the case
of the penetratin peptide (a 16-residue cell-penetrating
sequence from the Antennapedia homeodomain60), we found
that we needed two Ahx spacers between the CPP and the m3c
linker for the click reaction to reach completion, as this
relatively long cell-penetrating sequence appeared to otherwise
inhibit the click reaction presumably for steric reasons. Next, we
checked the TNKS2 ARC4 binding aﬃnities of the TAMRA-
labeled CPP-conjugated peptides using direct FP (Table S7).
For the Arg9 cell-penetrating sequence, when we used the two
Ahx spacers we observed a degree of non-speciﬁc binding to
TNKS2 ARC4, likely due to the arginine residues attached via
the long ﬂexible spacers competing with the binding peptide for
a hotspot interaction on the protein, and therefore, this
conjugate was not used further. We did not observe any non-
speciﬁc binding for the other CPP-conjugated peptides shown
in Table S7. All four exhibited TNKS binding aﬃnities that are
similar to that of the unconjugated counterpart T-cp4n2m3c.
We next tested the cell-penetrating capabilities of the TAMRA-
labeled peptides using U2OS and HEK 293T cells. Three of the
CPP-conjugated macrocyclized peptides, T-cp4n2m3c-R6, T-
cp4n2m3c-R9, and T-cp4n2m3c-Antp, showed signiﬁcant
ﬂuorescence spreading across the whole cell even at the lowest
Figure 7. Competition of peptides with GST-tagged human Axin1_1−
80 for binding to TNKS2 ARC4. The TNKS2 ARC4-Axin1_1−80
complex, immobilized on glutathione beads, was incubated with
increasing concentrations of peptide. After washing, the protein
remaining bound to the resin was run on SDS-PAGE. The TNKS2
ARC4 band was quantiﬁed using densitometry and normalized against
the GST-Axin1_1−80 band. The data are plotted relative to the
sample without peptide incubation (which was set at a value of 1).
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concentration of 10 μM. In contrast, T-cp4n2m3c-LCLR
(LCLR is a cell-penetrating tetrapeptide derived from the X-
protein of the hepatitis B virus61,62) and the non-conjugated
peptides T-cp4n2m3 and T-cp4n2m3c exhibited only punctate
ﬂuorescence indicative of endosomal entrapment, and the linear
peptide T-pep1 showed very weak ﬂuorescence or no
ﬂuorescence at all (Figure S12).
The Macrocyclized Peptides inhibit Wnt Signaling. A
dual-luciferase reporter (DLR) assay in Wnt-activated HEK
293T cells was used to determine the ability of the peptides to
modulate β-catenin levels and suppress Wnt transcription.
Unlabeled CPP-conjugates, rather than the TAMRA-labeled
versions, were used in the experiments because rhodamine-
based ﬂuorescent labels have been found to cause cytotoxicity
once they are transported intracellularly with the aid of CPP
peptides.63 Treatment of HEK 293T cells with an increasing
concentration of unlabeled peptide cp4n2m3c-Antp (contain-
ing the penetratin sequence on the linker) led to a dose-
dependent decrease in Wnt pathway reporter activity with an
IC50 around 50 μM (Figure 8). There was no observed change
in the level of the control Renilla luciferase activity, indicating
that peptide treatment had no eﬀect on transcription in general.
Moreover, treatment with non-cell-penetrating peptides pep1
or cp4n2m3c had no eﬀect on Wnt reporter activity, nor did
treatment with cp4n1m3c-Antp (a cell-penetrating version of
the non-binding peptide cp4n1m3c) (Table S2), thereby
satisfying these speciﬁcity controls. Figure S13 shows that
none of the unlabeled peptides were cytotoxic at the
concentrations used in the Wnt signaling assays.
■ SUMMARY
Here, we employed molecular dynamics simulations, two-
component double-click macrocyclization, and combinatorial
use of diﬀerent non-natural amino acids and cross-linkers to
constrain peptides that have extended bioactive conformations.
We demonstrate the application of this approach to design
inhibitors of the substrate-recognition domain of the TNKS
proteins whose activity is deregulated in numerous cancers.
One advantage of the two-component strategy is that the
peptide and the linker can be engineered separately and then
used in a combinatorial fashion to eﬃciently generate an array
of molecules. With the consensus-optimized substrate sequence
as a starting point, we used an iterative process of macro-
cyclized peptide design in which we varied the length and
rigidity of the linker as well as its position along the peptide.
The design was further guided by determining the crystal
structures of two of the macrocyclized peptides in complex with
TNKS. In this way, we identiﬁed peptides with submicromolar
TNKS binding aﬃnities that are proteolytically stable and
capable of disrupting the interaction between TNKS and the
Axin substrate in a dose-dependent manner. We exploited the
two-component nature of the macrocyclization method to
introduce cell-penetrating capability via the linker, and we
showed that these peptides are indeed able to enter cells and
modulate β-catenin levels. Thus, these macrocylized peptides
represent a promising new class of substrate-competitive
inhibitors of TNKS with potential for suppressing Wnt
signaling in cancer. Moreover, we have demonstrated that
double-click macrocyclization can be applied to non-helical,
extended, or irregularly structured peptide conformations; we
have also recently used it to develop constrained peptide
inhibitors of the hepatocyte nuclear factor 1β transcription
factor (HNF1β)−Importin α interaction in ovarian clear cell
carcinoma.64 Thus, the double-click macrocyclization strategy
has a broad scope, especially given the frequency with which
non-helical motifs are found in mediating PPIs.
■ EXPERIMENTAL SECTION
Molecular Dynamics Simulations. The structure of human
TNKS2 ARC4 bound to a 3BP2-derived peptide (PDB ID: 3TWR53)
was used to model the complex of TNKS2 ARC4 and the consensus
tankyrase-binding peptide. The 3BP2-derived peptide was truncated to
the core binding 8-residue motif (RSPPDGQS) and then modiﬁed
into the consensus peptide (REAGDGEE) by using the tleap module
of AMBER 11 to change the side chains of the mutated residues. The
consensus peptide was capped by acetyl and amide groups.
Protonation states of the complex were determined by PDB2PQR.65
The LEaP program in AMBER 11 was then used to solvate the
complex with TIP3P66 water molecules in a truncated octahedral box,
such that its walls were at least 9 Å away from any atom of the protein
or peptide, followed by neutralization of the system with seven sodium
ions.
Three independent explicit-solvent MD simulations of the modeled
tankyrase complex were carried out using diﬀerent initial atomic
velocities. A separate MD simulation of the unbound TNKS2 ARC4
was also carried out. Energy minimizations and MD simulations were
performed using the ﬀ99SB-ILDN67 force ﬁeld with the sander and
PMEMD modules of AMBER 11,68 respectively. SHAKE69 was
applied to constrain all bonds involving hydrogen atoms, allowing for a
time step of 2 fs. Non-bonded interactions were truncated at 9 Å,
whereas the particle mesh Ewald70 method was used to account for
long-range electrostatic interactions under periodic boundary con-
ditions. Weak harmonic positional restraints with a force constant of
2.0 kcal mol−1 Å−2 were placed on the complex’s non-hydrogen atoms
during the minimization and initial equilibration steps. Energy
minimization was carried out using the steepest descent algorithm
for 500 steps, followed by the conjugate gradient algorithm for another
500 steps. The system was then heated at constant volume to 300 K
over 50 ps, followed by equilibration at a constant pressure of 1 atm
for another 50 ps. Subsequent unrestrained equilibration (2 ns) and
production (50 ns) runs were carried out at a constant temperature of
300 K using a Langevin thermostat71 with a collision frequency of 2
ps−1 and a constant pressure of 1 atm using a Berendsen barostat72
with a pressure relaxation time of 2 ps.
The protein structures generated by the simulations were clustered
using the ART-2 algorithm73 based on the root-mean-square deviation
(RMSD) of the Cα atoms. Cut-oﬀ radii of 1.4 and 1.3 Å were used to
generate the clusters for the unbound and complex simulations,
respectively. The cluster members with the lowest RMSD from their
respective centroids were selected as representative structures for
structural alignment.
Figure 8. Eﬀect on Wnt-activated HEK 293T cells of treatment with
representative peptides. Error bars are those obtained from triplicate
sample measurements from two independent experiments.
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Computational Alanine Scanning. Computational alanine
scanning was carried out on the peptide from 200 equally spaced
complex structures extracted from the last 30 ns of the MD
simulations deemed stably equilibrated. The diﬀerences in the binding
free energies (ΔΔG) of the wild-type and alanine mutants (or glycine
mutant for Ala3) were calculated using the molecular mechanics/
generalized Born surface area (MM/GBSA) method.74 All programs
used for MM/GBSA calculations were part of AMBER 11. Molecular
mechanical energies were calculated with the sander module of
AMBER 11. The polar contribution to the solvation free energy was
calculated by the pbsa program using the modiﬁed GB model
described by Onufriev et al.,75 and the nonpolar contribution was
estimated from the solvent accessible surface area using the linear
combinations of pairwise overlaps method76 with γ set to 0.0072 kcal/
Å2 and β set to zero.77 The entropy term was not considered due to
the high computational cost and the assumption that the entropy of
the mutant does not diﬀer considerably from that of the wild type.78
Peptide Synthesis and Macrocyclization. The Fmoc-protected
azido-functionalized amino acids were synthesized as described
previously.79 All TNKS binding peptides were synthesized manually
on Rink Amide MBHA resin (0.65 mmol/g, 100−200 mesh,
Novabiochem) using a Vac-Man Laboratory Vacuum Manifold
(Promega) according to the standard Fmoc-based solid-phase peptide
synthesis (SPPS) method.80−82 The N-terminus of the peptide was
either capped by acetylation or coupled with a spacer aminohexanoic
acid followed by 5-carboxytetramethylrhodamine (5-TAMRA). Cell-
penetrating peptides were synthesized manually or on an automated
microwave peptide synthesizer (Liberty Blue, CEM) on Rink Amide
MBHA LL resin (0.38 mmol/g, 100−200 mesh, Novabiochem), and
linker m3c was attached to the N-terminal end of the peptides by
manual SPPS. All peptides were cleaved from the resin in a TFA
cocktail containing 92.5% (v/v) TFA, 2.5% (v/v) water, 2.5% (v/v)
triisopropylsilane, and 2.5% (v/v) dichloromethane. The eluate was
dried, and the cleaved peptide was precipitated with diethyl ether,
redissolved in 1:1 (v/v) water/acetonitrile, ﬁltered, and lyophilized.
The crude peptide was puriﬁed on a semi-preparative HPLC Agilent
1260 inﬁnity using a Supelcosil ABZ+PLUS column (alkyl-amide
phase, 250 mm × 21.2 mm, 5 μm), eluting with a linear gradient
system (solvent A: 0.1% (v/v) TFA in water; solvent B: 0.05% (v/v)
TFA in acetonitrile). The purity of the peptide was checked on an
analytical HPLC (Agilent 1260 Inﬁnity, Supelcosil ABZ+PLUS
column (150 mm × 4.6 mm, 3 μm)), eluting with a linear gradient
system (solvent A: 0.05% (v/v) TFA in water; solvent B: 0.05% (v/v)
TFA in acetonitrile). The puriﬁed peptides were lyophilized and
analyzed by LCMS.
The double-click reaction was carried out to cross-link the azido-
functionalized peptides with dialkynyl functionalized linkers.83 The
aliphatic linkers were purchased from Sigma-Aldrich, and all others
were synthesized according to protocols previously described.56−58 All
solvents for the reaction were degassed with nitrogen for 1 h before
use. The dialkynyl linker (1.1 equiv) was added to the diazido-peptide
in 1:1 (v/v) water and tert-butanol under nitrogen before the addition
of a solution of copper(II) sulfate pentahydrate (1 equiv), tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA, 1 equiv), and sodium
ascorbate (3 equiv) in water. The reaction mixture was stirred for 16 h
at room temperature and monitored by LCMS. A second aliquot of
linker and catalyst was added for those reactions that had not run to
completion. The crude product was puriﬁed on the semi-preparative
HPLC as described above. The puriﬁed macrocyclized peptide was
lyophilized and analyzed by infrared spectrometry (IR) and high-
resolution mass spectrometry.
Protein Puriﬁcation. Genes for human TNKS1_179−966 and
TNKS2_488−649 were purchased from Epoch Life Science, and that
for human Axin1_1−80 was purchased from Life Technologies.
TNKS1_315−662, TNKS2_488−649, Axin1_1−43, Axin1_1−80
were cloned into expression vector pRSETa (GE Healthcare) or
pGEX using standard molecular biology methods. Proteins were
expressed and puriﬁed according to procedures reported previously
with modiﬁcations.53,54 The plasmid containing each construct was
transformed to E. coli C41(DE3) cells, and the colonies were grown in
2TY media at 37 °C until OD 600 reached 0.6−1.0 and were then
induced at 20−25 °C with 0.2−0.5 mM IPTG for 16 h. Cell pellets
were collected and resuspended in 50 mM Tris·HCl buﬀer pH 8.0, 500
mM NaCl, 2 mM DTT, protease inhibitor cocktail (Sigma-Aldrich),
10 mM EDTA for GST-tagged TNKS2_488−649, Axin1_1−43, and
Axin1_1−80. For His6-tagged TNKS1_315−662, 10 mM EDTA was
replaced with 10 mM imidazole. The cells were lysed using an
Emulsiﬂex C5 homogenizer, and the lysate was added to either Ni-
NTA agarose (QIAGEN) or Glutathione Sepharose 4B beads (GE
Healthcare). The bound His6- or GST-tagged protein was washed with
the same resuspension buﬀer but without the protease inhibitor, and
the tag was cleaved with thrombin (25 U per liter of culture) overnight
at 25 °C. The desired protein was puriﬁed to >95% homogeneity on a
size-exclusion gel-ﬁltration column (HiLoad 16/60 Superdex G75)
equilibrated with loading buﬀer of 50 mM HEPES buﬀer pH 7.5, 300
mM NaCl, 2 mM DTT. For protein crystallization, TNKS2_488−649
was expressed and puriﬁed using the same protocol, except that the
loading buﬀer was 20 mM HEPES buﬀer pH 7.5, 150 mM NaCl, 0.5
mM TCEP.
X-ray Crystallography. For the cocrystal structure of TNKS2
488−649 in complex with cp4n4m5, 0.3 μL of 1 mM TNKS2_488−
649 and 5 mM cp4n4m5 in 20 mM HEPES pH 7.5, 150 mM NaCl,
0.5 mM TCEP, 5% (v/v) DMSO were mixed with 0.3 μL of
precipitant solution containing 1.60 M trisodium citrate in a sitting
drop vapor diﬀusion experiment at 19 °C. Plate-like crystals grew to
their ﬁnal size in 14 days. For the crystal structure of TNKS2 488−649
in complex with sp4n2m3, a mixture of 0.3 μL of 1 mM TNKS2_488−
649 and 2.9 mM cp4n2m3 in 10 mM HEPES pH 7.5, 75 mM NaCl,
0.25 mM TCEP, 5% (v/v) DMSO was mixed with 0.3 μL of
precipitant solution containing 3.20 M ammonium sulfate and 0.1 M
trisodium citrate pH 5.0 in a sitting drop vapor diﬀusion experiment at
19 °C. Needle-like crystals appeared after 4 days and grew to the ﬁnal
length of 420 μm after 12 days. Data were collected at Diamond Light
Source beamlines I24 and I04-1 and processed with autoPROC84/
XDS85 to 1.35 and 1.33 Å, respectively (Table S3). Phases were
obtained through molecular replacement using PHASER86 with PDB
3TWQ53 as the search model. Iterative model building and reﬁnement
were subsequently performed with Coot87 and REFMAC5.88 The
structures have been deposited in the Protein Data Bank with codes
5BXU (TNKS2 ARC4−cp4n4m5 complex) and 5BXO (TNKS2
ARC4−cp4n2m3 complex). For the comparative analysis, the Cα-
atoms of the TNKS2 residues were aligned within a 7 Å radius around
the peptide/macrocycle binding site to avoid changes in curvature
having a signiﬁcant impact on the analysis.
Fluorescence Polarization Assays. Fluorescence polarization
(FP) assays were performed in 96-well half area black microplates
(Corning) on a CLARIOstar microplate reader (BMG labtech) using
excitation ﬁlter 540−20 nm, dichroic mirror LP 566 nm, and emission
ﬁlter 590−20 nm. All peptides were dissolved in water as stock
solutions. For direct FP assays, the stock concentrations of the
TAMRA-labeled peptides were determined based on the 5-TAMRA
absorbance at 556 nm (extinction coeﬃcient ε = 89,000 M−1 cm−1)
measured on a NanoDrop 2000 (Thermo Scientiﬁc) and veriﬁed by
amino acid analysis (Department of Biochemistry, University of
Cambridge). TNKS2 ARC4 (488−649) or TNKS1 ARC2−3 (315−
662) was diluted 2-fold serially in the assay buﬀer (50 mM HEPES pH
7.5, 300 mM NaCl, 2 mM DTT, 0.05% (v/v) Tween 20) for a 12-
point titration curve in triplicate. The diluted TAMRA-labeled peptide
(20 nM, 50 μL) was mixed with the serially diluted TNKS2 ARC4 or
TNKS1 ARC2−3 (40−0 μM, 50 μL) in each well and incubated for
30 min at 25 °C before the measurement. Data were analyzed on
GraphPad Prism 5.0, and the dissociation constant, Kd, was
determined using the following equation assuming the ratio between
the concentration of the bound and that of the total TAMRA-labeled
peptide is proportional to the ﬂuorescence polarization
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where FP is the ﬂuorescence polarization, B is the minimum FP, T is
the maximum FP, L0 is the total concentration of TAMRA-labeled
peptide, P0 is the total concentration of protein, and Kd is the
dissociation constant.
For the competition FP assays, the stock concentrations of the
unlabeled macrocyclized peptides or the Axin1 fragments were
determined by amino acid analysis. TAMRA-labeled pep1 (20 nM)
and TNKS2 ARC4 (3 μM) or TNKS1 ARC2−3 (1.2 μM) were
incubated in PBS buﬀer containing 0.05% (v/v) Tween 20. The
unlabeled peptide or Axin1 fragment was diluted 2-fold serially in PBS
buﬀer containing 0.05 (v/v) Tween 20 for a 12-point titration curve in
triplicate. The diluted peptide or Axin1 fragment (50 μL) was mixed
with the TAMRA-pep1/TNKS solution (50 μL) in each well and
incubated for 30 min at 25 °C before the measurement was taken.
Titrations were performed in triplicate. Data were ﬁtted in GraphPad
Prism 5.0 using the equations as described previously.89
Circular Dichroism (CD) Spectroscopy. CD spectra were
recorded on a Chirascan CD spectrometer (Applied Photophysics),
ﬁtted with a water bath and using a 1 mm path length cell. Unlabeled
peptides (0.1 mM) were prepared in water, and the spectra were
recorded at 25 °C. Four separate measurements were made, and the
mean molar ellipticity, θ, was then plotted against the wavelength.
Isothermal Titration Calorimetry (ITC). All ITC experiments
were performed on a MicroCal iTC200 (GE Healthcare) at 25 °C.
TNKS2 ARC4 (488−649), TNKS1 ARC2−3 (315−662), and Axin1
fragments were dialyzed overnight in PBS and 0.5 mM TCEP.
Unlabeled peptides were used in the experiments. The peptide was
diluted from the stock solution using the same dialysis buﬀer, and the
eﬀect of buﬀer dilution was accounted for when preparing TNKS
samples. TNKS2 ARC4 (160−280 μM) or TNKS1 ARC2−3 (60−150
μM) was titrated into the sample cell containing the peptide (5−15
μM) or Axin1 fragments (8−12 μM) with an initial injection of 0.2 μL
over 0.4 s followed by 19 injections of 2 μL over 4 s with a spacing of
60 s, except for TNKS2 ARC4 and Axin1 fragments for which the
spacing was 70 s. Control experiments were performed using the same
settings as above except that the cell was ﬁlled with dialysis buﬀer.
Data were ﬁtted with nonlinear regression using a one-site binding
model from Origin 7.0 (MicroCal, Inc.).90
Pull-Down Assay. GST-tagged human Axin1_1−80 was incubated
with Glutathione Sepharose 4B beads (GE Healthcare) for 1 h at 4 °C.
The beads were washed 3 times with wash buﬀer (50 mM Tris·HCl
pH 8.0, 500 mM NaCl, 2 mM DTT). Approximately 80 μg of GST-
tagged Axin1_1−80 (10 μL) on beads was incubated with TNKS2
ARC4 (40 μL, 89 μM) or His6-tagged TNK1 ARC2−3 (50 μL, 100
μM) for 0.5 h at room temperature. The unbound TNKS protein was
washed away with wash buﬀer (150 μL × 2), and the beads were
incubated at room temperature for 0.5 h with the serially diluted
unlabeled peptide (50 μL, 0−200 μM). The beads were subsequently
washed twice (150 μL × 2), boiled with SDS, and loaded on the SDS-
PAGE protein gels. After the run, the gels were stained with
Coomassie Brilliant Blue and imaged. The intensities of the bands
were analyzed using ImageJ, and the standard deviations were
calculated from two independent experiments.
Proteolytic Degradation. Endoproteinase AspN (50 ng, New
England BioLabs) was added to a mixture of TAMRA-labeled peptide
(400 μM), TAMRA (100 μM), and Endoproteinase AspN enzyme
buﬀer (New England BioLabs), and the volume was made up to 50 μL
with sterile water. The reaction was incubated with shaking at 550 rpm
at 25 °C. At each time point, a 5 μL aliquot was taken and centrifuged
at 10,000 rpm at 4 °C, and the supernatant was diluted 4 times with
water before being loaded onto an analytical HPLC (Agilent 1260
Inﬁnity, Supelcosil ABZ+PLUS column (150 mm × 4.6 mm, 3 μm))
and eluted with a linear gradient system (solvent A: 0.05% (v/v) TFA
in water; solvent B: 0.05% (v/v) TFA in acetonitrile). TAMRA-labeled
T-pep1 was run with a linear gradient of 5−95% solvent B over 5 min,
and TAMRA-labeled cp4n2m3 was run with 5−40% solvent B over 20
min. The cleavage of the TAMRA-labeled peptide was monitored at
550 nm, and the integral of the peptide peak was measured against that
of TAMRA as the internal standard. After 270 min, the remaining
sample containing TAMRA-labeled T-cp4n2m3 was submitted to
LCMS, and no mass corresponding to the hydrolyzed macrocyclized
peptide could be observed. The plot (Figure S10a) is representative of
one of the two independent experiments.
Cellular Uptake Assay. U2OS or HEK 293T cells were grown to
100% conﬂuency before being used in all assays. Cells (106) were
seeded in glass-bottom dishes (35 mm diameter, MatTek Corpo-
ration) and grown for 16 h at 37 °C and 5% CO2 in 1 mL of DMEM
(1×) + GlutaMAX-1 (Life Technologies). Cells were then incubated
with TAMRA-labeled peptides (10−40 μM) for 4.5 h, followed by a
further 0.5 h incubation with Hoechst 33342 nucleic acid stain (5 μg/
mL) at 37 °C and 5% CO2 before being washed with PBS (2 × 1 mL)
and replenished with 1 mL of HBSS (1×) (Life Technologies).
Confocal images were taken at 37 °C on a Leica TCS SP5 confocal
microscope with sequential excitation at 405 and 543 nm, respectively.
The gains were adjusted to be the same among all cell samples.
Cell Toxicity Assay. U2OS cells (2 × 105) or HEK 293T cells (2
× 105) were seeded in a 96-well cell culture plate (Corning Costar)
and grown for 16 h at 37 °C and 5% CO2 in 100 μL of DMEM (1×) +
GlutaMAX-1 (Life Technologies) containing 10% (v/v) fetal bovine
serum and penicillin-streptomycin. Cells were then incubated with the
unlabeled peptides (50 and 100 μM) for 5 h at 37 °C and 5% CO2. A
maximum LDH release control was prepared by adding 10× Lysis
Solution (10 μL, Promega) to the cells and incubated at 37 °C for 45
min before the measurement. The supernatant (50 μL) from each well
was transferred to a clear ﬂat-bottom 96-well microplate, and the assay
was performed using a CytoTox 96 Nonradioactive Cytotoxicity Assay
(Promega) according to the manufacturer’s protocol. The LDH
release indicated by the absorbance at 490 nm was measured on a
CLARIOstar microplate reader (BMG Labtech). Data were obtained
from triplicate samples, and the standard deviations were calculated
from two independent experiments.
TOPFLASH Assay. HEK 293T were grown in Dulbecco’s Modiﬁed
Eagles Medium (DMEM) supplemented with 10% fetal calf serum.
Wnt pathway activity was induced by treating cells with 20 mM LiCl
(or KCl as control) or conditioned media obtained from L-cells
expressing Wnt3A for 6 h. Cells were transfected with the
Lipofectamine 2000 transfection reagent according to the manufac-
turer’s protocol (Invitrogen).
For TOPFLASH reporter assays, 100 ng of TOPFLASH plasmid
and 10 ng of CMV-Renilla plasmid (as internal control) were used to
transfect cells in 24-well plates. Transfected cells were allowed to
recover for 8 h, and concurrently treated with unlabeled macrocyclized
peptides and Wnt3A conditioned media/LiCl for a further 16 h.
TOPFLASH assays were performed using the Dual-Luciferase
Reporter Assay System (Promega) as previously described.91 Relative
luciferase values were obtained from triplicate samples (from two
independent experiments) by dividing the ﬁreﬂy luciferase values
(from TOPFLASH) by the Renilla luciferase values (from CMV-
renilla), and standard deviations were calculated.
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